The data highlighted a positive shift in investor outlook and an encouraging trend for broader market participation.

Sentiment for the stock, which has shed 15 per cent over the past three months, continues to remain bearish given the weak ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...